News

At the 2023 American Society of Retina Specialists meeting in Seattle, Washington, we asked some of the presenters, "What research here do you find exciting or interesting?" Here's what Diana Do, MD, Shawn Kavoussi, MD, and Durga Borkar, MD, MMCi had to say!

Prevent Blindness declares September as Sports Eye Safety Month to educate the public on the risk of significant eye injuries and the need for the proper sports eye protection.

At the 2023 American Society of Retina Specialists meeting in Seattle, Washington, we asked some of the presenters, "What research here do you find exciting or interesting?" Here's what Ursula Schmidt-Erfurth, MD, Veena Raiji, MD, and Dante Pieramici, MD had to say!

According to the university, a special antibody that is derived from llamas, called a nanobody, can stop the misfolding and the activation of Rhodopsin, a molecule whose mutations can lead to blindness.

"What research at the 2023 ASRS meeting do you find exciting or interesting?" Here's what Aaron Lee, MD, Megan Baldwin PhD, and Carl Danzig, MD had to say!

According to the Keck School of Medicine of USC, the $12.4 million from the California Institute for Regenerative Medicine is the latest round of support for USC researcher Mark Humayun and a milestone in the development of a stem cell patch to treat advanced dry age-related macular degeneration.

According to Outlook Therapeutics, it is working with the FDA to address the agency’s issues.

The study from New Zealand was conducted on an otherwise healthy 28-year-old woman.

According to the company, it is anticipating cost savings of up to $300 million through 2024, which includes an estimated 25% reduction in current workforce and a reduction in external expenses.

ATSN-201 leverages novel spreading capsid to overcome challenges associated with intravitreally delivered AAVs in the treatment of XLRS.

More than 135 patients have been recruited in 4 months for Phase 2 study of a single intravitreal (IVT) injection of ONL1204 ophthalmic solution as an adjunct to standard-of-care surgery.

The research by Scott N J Watamaniuk, PhD, has potential implications for patients diagnosed with strabismus.

TRS01 demonstrates clear anti-inflammatory activity in noninfectious anterior uveitis with no evidence of significant adverse effects.

Amber is leveraging a multi-kilobase RNA editing platform to expand the reach of treatable pathogenic variants.

Priya Vakharia, MD, spoke with our team about her presentation at the Women in Ophthalmology Summer Symposium being held in Marco Island, Florida.

Sruthi Arepalli, MD, spoke with our team about the current landscape of geographic atrophy (GA) and her presentation at the Women in Ophthalmology Summer Symposium being held in Marco Island, Florida.

The 3D viewing systems and digital microscopes offer numerous advantages for performing the procedures.

Maria H. Berrocal spoke with our team about her presentation at the Women in Ophthalmology Summer Symposium being held in Marco Island, Florida.

Commonly used immunosuppressants used in the short term to control an ocular inflammatory disease were not associated with increased risk of developing cancer later.

Kiora Pharmaceuticals Inc. has been granted US and European Patents covering local ocular delivery of the KIO-100 family of non-steroidal, anti-inflammatory small molecules.

The company believes the 19-gauge filter needles may be the culprit in the SYFOVRE injections.

Researchers successfully transplanted human microglia cells into a mouse retina to create a model that could be used to test new treatments for incurable eye diseases.

European Medicines Agency issued approval for a Clinical Trial Application of its new gene therapy, VG901, which uses an adeno-associated virus vector to treat CNGA1-associated retinitis pigmentosa.

Optical coherence tomography analysis of measurements of cystoid macular lesions showed that patients with different IRD phenotypes can develop very large CMLs.

Researchers have identified markers that indicate the presence of Parkinson’s disease in patients an average of 7 years before the disease presents clinically.

The findings of this study shed new light on processes such as learning and memory but also the development of blinding conditions.

According to Regeneron, the approval was based on data in the PULSAR and PHOTON trials, in which the drug demonstrated clinically equivalent vision gains to aflibercept Injection 2 mg that were maintained with fewer injections.

Adverum Biotechnologies, Inc. provided an update on the company’s ongoing Phase 2 LUNA trial evaluating ixoberogene soroparvovec (Ixo-vec) for the treatment of wet age-related macular degeneration (wet AMD).

The FDA has assigned a Prescription Drug User Fee Act (PDUFA) action date for APP13007 of March 4, 2024.

Astellas Pharma Inc. announced the European Medicines Agency (EMA) has accepted for regulatory review the marketing authorization application (MAA) for Iveric Bio’s avacincaptad pegol (ACP).